SOAT1 and atopic eczema: Isoliquiritin downregulates the JAK/STAT signaling pathway by inhibiting the phosphorylation of JAK2, STAT1, STAT3, and STAT5, thereby regulating immune and inflammation responses and contributing to the treatment of atopic dermatitis (Wu et al., 2022).